Nasdaq Stockholm Welcomes CombiGene to First North

Stockholm, December 19, 2018— Nasdaq (Nasdaq: NDAQ) announces that the trading in CombiGene AB’s shares (short name: COMBI) will commence today on Nasdaq First North in Stockholm. CombiGene belongs to the health care sector and is the 83^rd company to be admitted to trading on Nasdaq’s Nordic markets* in 2018.

CombiGene has, by combining advancements in neuroscience and modern gene therapy, developed a treatment method which is shown to prevent epileptic seizures. Currently, CombiGene is focusing on further developing this treatment for the benefit of epilepsy patients. The company’s knowledge and experience can also be put to use for developing effective gene therapies for other difficult-to-treat diseases for which adequate treatment methods are currently lacking. CombiGene’s office is located at Medicon Village in Lund and the company is built on research results from Lund University and the University of Copenhagen. For more information, please visit www.combigene.com.

“The switch to Nasdaq First North will increase the awareness of CombiGene and attract a larger group of investors and accordingly it will give the company better access to both Swedish and International capital,” said Jan Nilsson CEO of CombiGene. “Given the strong progress of our epilepsy project and the growing international interest, the switch to Nasdaq First North is a very natural step to take.”

”We welcome CombiGene to Nasdaq First North,” said Adam Kostyál, SVP and Head of European Listings, Nasdaq. “CombiGene joins our growing health care sector and we congratulate the company on its successful listing.”

CombiGene AB has appointed FNCA Sweden AB as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 100 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to over 4,000 total listings with a market value of approximately $15 trillion. To learn more, visit business.nasdaq.com.

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.